Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinqiaomai Capsules is a traditional Chinese medicine (TCM) product developed and manufactured by Jinghua Pharmaceutical Group. It is derived from the rhizome of *Fagopyrum dibotrys* (also known as wild buckwheat or Jinqiaomai). The medication is primarily used for the treatment of respiratory tract infections, including lung abscesses, acute and chronic bronchitis, and tonsillitis. Its pharmacological effects are attributed to its ability to clear heat, remove toxins, and promote the discharge of pus. It contains active constituents such as flavonoids and condensed tannins which may contribute to its anti-inflammatory and antibacterial properties. In the Chinese market, it is often marketed under the brand name Ningning.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jinqiaomai Capsules.